Copertina

Clinical Utility of Deutetrabenazine as a Treatment Option for Chorea Associated with Huntington’s Disease and Tardive Dyskinesia

Samuel Frank,1 Aljoharah Alakkas2 1Department of Neurology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, USA; 2Department of Neurology, National Neuroscience Institute, King Fahad Medical City, Riyadh, K.S.ACorrespondence: Samuel Frank, Department of Neurology, Beth Israe...

Descrizione completa

Salvato in:

Dettagli Bibliografici
Autori principali:	Frank S (Autore), Alakkas A (Autore)
Natura:	Libro
Pubblicazione:	Dove Medical Press, 2023-12-01T00:00:00Z.
Soggetti:	article
Accesso online:	Connect to this object online.
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia
di: Claassen Daniel O. MD, et al.
Pubblicazione: (2023)

Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease
di: Dean M, et al.
Pubblicazione: (2018)

A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine
di: Rikinkumar S. Patel, et al.
Pubblicazione: (2019)

Tardive dyskinesia
di: Violetta A. Tolmacheva
Pubblicazione: (2021)

Pathophysiology, prognosis and treatment of tardive dyskinesia
di: Hiroyoshi Takeuchi, et al.
Pubblicazione: (2022)

New and emerging treatments for symptomatic tardive dyskinesia
di: Rana AQ, et al.
Pubblicazione: (2013)

Improvement of Tardive Dyskinesia during Mindfulness Meditation
di: Maria Angela Santoro, et al.
Pubblicazione: (2021)

Pimozide-induced tardive dyskinesia in the treatment of delusions of infestation
di: Rodrigo A. Gutierrez, BS, et al.
Pubblicazione: (2024)

Tardive dyskinesia: understanding current challenges in diagnosis and treatment
di: David Taylor, et al.
Pubblicazione: (2023)

Huntington's chorea in a child. the first description of the disease in ukraine. proper observation
di: T. Stetsenko, et al.
Pubblicazione: (2019)

The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation
di: Robert H. Farber, et al.
Pubblicazione: (2024)

Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders
di: Chang FC, et al.
Pubblicazione: (2014)

Tardive Dyskinesia, Oral Parafunction, and Implant-Supported Rehabilitation
di: S. Lumetti, et al.
Pubblicazione: (2016)

Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies
di: Evangelia Eirini Tsermpini, et al.
Pubblicazione: (2022)

Association Study of the Complement Component C4 Gene in Tardive Dyskinesia
di: Clement C. Zai, et al.
Pubblicazione: (2019)

Tardive Dyskinesia After Aripiprazole Treatment That Improved With Tetrabenazine, Clozapine, and Botulinum Toxin
di: Lourdes Aguilar, et al.
Pubblicazione: (2019)

Impact of a pharmacist-driven tardive dyskinesia screening service
di: Niyati Butala, PharmD, BCPP, et al.
Pubblicazione: (2021)

Management of Huntington’s disease: role of tetrabenazine
di: Marina de Tommaso, et al.
Pubblicazione: (2011)

Restless tongue: Lingual Tardive Dyskinesia - A rare case report
di: Pritesh Ruparelia, et al.
Pubblicazione: (2022)

Digital functionally generated path technique in a tardive dyskinesia patient
di: A/Prof Du Hyeong Lee, et al.
Pubblicazione: (2023)

Current perspectives on the epidemiology and burden of tardive dyskinesia: a focused review of the clinical situation in Japan
di: Yasuhiro Mori, et al.
Pubblicazione: (2022)

Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States
di: Rakesh Jain, et al.
Pubblicazione: (2023)

Physical Function-Tardive Dyskinesia (PATD) on Critical Patients in Intensive Care Unit
di: Heru Suwardianto, et al.
Pubblicazione: (2017)

Investigation of the HSPG2 Gene in Tardive Dyskinesia - New Data and Meta-Analysis
di: Clement C. Zai, et al.
Pubblicazione: (2018)

Parkinson’s Disease: Carbidopa, Nausea, and Dyskinesia [Retraction]
di: Hinz M, et al.
Pubblicazione: (2021)

Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations
di: Jungjin Kim, et al.
Pubblicazione: (2014)

Psychotropic Medications-Induced Tardive Dyskinesia and Associated Factors Among Patients with Mental Illness in Ethiopia
di: Kumsa A, et al.
Pubblicazione: (2020)

Correction: Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States
di: Rakesh Jain, et al.
Pubblicazione: (2024)

A Study on Drug-Induced Tardive Dyskinesia: Orofacial Musculature Involvement and Patient's Awareness
di: Arunachalam M Anusa, et al.
Pubblicazione: (2018)

Parkinson’s Disease: Carbidopa, Nausea, and Dyskinesia [Expression of Concern]
di: Hinz M, et al.
Pubblicazione: (2020)

Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials
di: Solmi M, et al.
Pubblicazione: (2018)

Transgenic animal models for study of the pathogenesis of Huntington’s disease and therapy
di: Chang RB, et al.
Pubblicazione: (2015)

Altered DNA methylation of CYP2E1 gene in schizophrenia patients with tardive dyskinesia
di: Ping Zhang, et al.
Pubblicazione: (2022)

Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report
di: Shintaro Sakai, et al.
Pubblicazione: (2021)

(+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia
di: Wenyan Wang, et al.
Pubblicazione: (2021)

Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers
di: Frank Schneider, et al.
Pubblicazione: (2020)

Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study
di: Caroline M. Tanner, et al.
Pubblicazione: (2023)

Supplemental Treatment for Huntington's Disease with miR-132 that Is Deficient in Huntington's Disease Brain
di: Masashi Fukuoka, et al.
Pubblicazione: (2018)

Benign Hereditary Chorea
di: J Gordon Millichap
Pubblicazione: (1993)

Sydenham's Chorea Therapy
di: J Gordon Millichap
Pubblicazione: (1988)